RESEARCH-USE BIOSIMILAR ANTIBODY
Teneliximab
Monoclonal antibody · IgG1
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.
TARGETTNFRSF5
YMonoclonal antibody
CATALOGSC-BS-127
CATALOG NUMBERSC-BS-127
MOLECULAR WEIGHTApprox. 146.06 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.
Teneliximab is a recombinant research-use antibody directed against TNFRSF5.